Full-Time

Senior Director

Biostatistics

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$226.4k - $339.6k/yr

+ Bonus + Equity Awards

Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible role allows for remote work up to two days per week or on-site work five days per week.

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
SAS
R
Requirements
  • Ph. D. in Statistics or Biostatistics
  • Typically requires 12 years of experience with a Ph.D. or the equivalent combination of education and experience
  • Prior people management experience required
  • Previous project/process leadership experience required
  • NDA/MAA experience and direct dealings with US or European regulators
  • Significant expertise with SAS and R statistical software
  • Demonstrated expertise in advanced/complex statistical methods used in drug development
Responsibilities
  • Defines and implements the technical and strategic direction of assigned area of responsibility, guiding technological innovation and process improvements aligned to Biostatistics Functional/Departmental objectives.
  • Oversees, manages, and directs multiple key projects, providing both strategic and technical expertise, and including clinical trials, observational studies, real world data (RWD) investigations, or other scientific research.
  • Contributes to drug development strategy including clinical development plans and lifecycle management planning documents.
  • Develops technical leadership, guides project teams to more meaningful and/or productive ends. Sets the technical and scientific directions of the project(s).
  • Oversees the delivery of KRMs, conducts senior review of protocols, CSRs, publications, and statistics related documents for regulatory interaction, and approves SAPs.
  • Contributes or oversees the statistical contributions to external interactions with regulators, payers, review boards, etc.
  • Key contributor to Statistical Review Forum (SRF) to enable statistical excellence and Biometrics strategic input in study design and planning.
  • Authors or co-authors methodological or study-related publications and posters.
  • Leads or oversees development and implementation of innovative designs and analysis methods.
  • Oversees or contributes in a leading role to departmental working group efforts on various technical and operational issues.
  • Oversees the performance of project team members, ensuring proper level of scientific rigor, effective team operation and cross-functional collaboration.
  • May contribute to the management of the biostatistics department as a member of the departmental senior leadership team.
  • Represents Biostatistics at leadership meetings and senior management reviews.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.